Evofem Biosciences, Inc. (NASDAQ: EVFM) Collaborates with Emmy® Award-winning actress Annie Murphy To Generate Awareness on Hormone-free Contraceptive; Phexxi

Women should call the shots when it comes to their bodies, including making decisions on their quality of life and, more particularly, birth control methods. And to generate more awareness on women’s sexual and reproductive health, Evofem Biosciences, Inc. (NASDAQ: EVFM) has partnered with Annie Murphy, an Award-winning actress. The duo is launching a national campaign dubbed “House Rules,” to educate women about Phexxi, Evofem’s hormone-free contraceptive.

Listen to Murphy’s birth control journey. You will understand why she is so passionate about empowering women to choose the suitable birth control method and also live by their “rules.” 

Phexxi is the First and Only FDA-Approved Hormone-free Birth Control Product 

Murphy took ten years to discover the proper hormonal birth control method. She cycled through multiple options before settling on Phexxi, the first and only FDA-approved use-it-only-when-you-need-it prescription vaginal gel. It is on-demand and gives women control of their sex life. However, it is not effective if used after sex and does not protect against sexually transmitted infections. In addition, victims of repeated urinary tract problems should not use Phexxi. 

Nonetheless, CEO of Evofem Biosciences, Saundra Pelletier, said, “… we are excited to help bring greater awareness to Phexxi…We are amplifying Phexxi through Annie’s “House Rules” because we know that some women may experience side effects from synthetic hormones….”

In other news, EVFM is delighted to present seven data sets from clinical trials of Phexxi at four medical society meetings in October 2021. There is a tremendous desire from local and international healthcare providers to learn more about Evofem’s vaginal pH modulator. And according to the Head of Medical Affairs, Brandi Howard, they anticipate providing important clinical insights in support of Phexxi.

It is worth mentioning that Evofem is targeting a $2.4B US market opportunity of women’s contraceptives. A 47% growth in Phexxi prescriptions in Q2 2021 from the previous quarter is a clear indicator of aggressive its advancement in addition to discussions for its commercialization in international markets.